{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:47:53Z","timestamp":1793296073096,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004835","name":"Zhejiang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008235","name":"School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004476","name":"Chinese Center for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jgar.2022.07.019","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T08:50:37Z","timestamp":1659171037000},"page":"418-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Evaluation of HIV-1 drug resistance among patients failing first-line antiretroviral therapy in Ethiopia"],"prefix":"10.1016","volume":"30","author":[{"given":"Yimam","family":"Getaneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desta","family":"Kassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjie","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.07.019_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-017-2550-8","article-title":"HIV-1 genetic diversity and primary drug resistance mutations before large-scale access to antiretroviral therapy, Republic of Congo","volume":"10","author":"Niama","year":"2017","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jgar.2022.07.019_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-018-0206-y","article-title":"Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay","volume":"15","author":"Silver","year":"2018","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jgar.2022.07.019_bib0003","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1590\/S1020-49892011001200025","article-title":"HIV transmitted drug resistance in adult and pediatric populations in Panama","volume":"30","author":"Castillo","year":"2018","journal-title":"Rev Panam Salud P\u00fablica"},{"key":"10.1016\/j.jgar.2022.07.019_sbref0004","article-title":"Understanding fast-track targets. Accelerating action to end the AIDS epidemic by 2030","volume":"12","author":"UNAIDS","year":"2020","journal-title":"Unaids"},{"key":"10.1016\/j.jgar.2022.07.019_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/135965350801302S07","article-title":"World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites","volume":"13","author":"Jordan","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2022.07.019_bib0006","first-page":"52","article-title":"Associated with antiviral therapy","volume":"55","author":"Bartholomeusz","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2022.07.019_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005886","article-title":"HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China","volume":"4","author":"Leng","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jgar.2022.07.019_bib0008","unstructured":"Ethiopian Public Health Institute, Addis Ababa E. HIV drug resistance early warning indicators survey in Ethiopia. http:\/\/www.ephi.gov.et\/images\/pictures\/HIV. Drug Resistance Early warning indicators survey.pdf; 2013 [accessed 07 Feburay 2022]."},{"key":"10.1016\/j.jgar.2022.07.019_bib0009","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2147\/IDR.S196448","article-title":"Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam","volume":"12","author":"Tien","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2022.07.019_sbref0010","series-title":"The strategic use of antiretrovirals to help end the HIV epidemic","first-page":"54","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.jgar.2022.07.019_bib0011","first-page":"335","article-title":"The molecular epidemiology of adenovirus","volume":"103","author":"Aoki","year":"1999","journal-title":"J Japanese Ophthalmol Soc"},{"key":"10.1016\/j.jgar.2022.07.019_bib0012","first-page":"46","article-title":"HIV-1 treatment failure among population taking antiretroviral therapy in Ethiopia","volume":"1","author":"Getaneh","year":"2019","journal-title":"J AIDS HIV Treat"},{"key":"10.1016\/j.jgar.2022.07.019_bib0013","series-title":"Guidel Surveill Drug Resist Tuberc","first-page":"2011","volume":"9","author":"The World Health Organization","year":"2018"},{"key":"10.1016\/j.jgar.2022.07.019_bib0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijid.2020.02.031","article-title":"HIV drug resistance early warning indicators in Ethiopia: variability at regional and health facility levels and trend over time","volume":"95","author":"Getaneh","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.019_bib0015","first-page":"1","article-title":"National consolidated guidelines for comprehensive HIV prevention, care, and treatment","author":"Federal Ministry of Health","year":"2018","journal-title":"Fmoh"},{"key":"10.1016\/j.jgar.2022.07.019_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0028184","article-title":"Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.019_sbref0017","series-title":"4 clinical guidelines: antiretroviral therapy. Consol Guidel Use Antiretrovir Drugs Treat Prev HIV Infect Recomm a Public Heal Approach","first-page":"129","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.jgar.2022.07.019_bib0018","unstructured":"World Health Organisation. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating 2018. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/277395\/WHO-CDS-HIV-18.51-eng.pdf?ua=1. [accessed 09 March 2022]"},{"key":"10.1016\/j.jgar.2022.07.019_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012718","article-title":"Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 seroconverter cohort","volume":"5","author":"Bartmeyer","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.019_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v10020060","article-title":"High levels of dual-class drug resistance in HIV-infected children failing first-line antiretroviral therapy in Southern Ethiopia","volume":"10","author":"Tadesse","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.jgar.2022.07.019_bib0021","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1371\/journal.pone.0023091","article-title":"HIV drug resistance (HIVDR) in antiretroviral therapy-na\u00efve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high","volume":"6","author":"Kasang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.019_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0230451","article-title":"Population-based monitoring of HIV drug resistance early warning indicators in Uganda: a nationally representative survey following revised WHO recommendations","volume":"15","author":"Asio","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.019_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241071","article-title":"HIV drug resistance profile in South Africa: Findings and implications from the 2017 national HIV household survey","volume":"15","author":"Moyo","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.019_bib0024","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1371\/journal.pone.0205446","article-title":"HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003\u20132013","volume":"13","author":"Arimide","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.019_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.019_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-017-2893-1","article-title":"Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N\u2019Djamena, Chad: findings from a cross-sectional study","volume":"10","author":"Adawaye","year":"2017","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jgar.2022.07.019_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0232649","article-title":"Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania","volume":"15","author":"Mziray","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.019_bib0028","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1468-1293.2009.00747.x","article-title":"Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment","volume":"11","author":"Murillo","year":"2010","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2022.07.019_bib0029","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/135965350400900514","article-title":"Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe","volume":"9","author":"Pillay","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2022.07.019_bib0030","first-page":"169","article-title":"Identification of I50L as the Signature Ataz (ATV)-Resistance Mutation in Treatment-N HIV-1-Infected Patients Receiving ATV-Containing Regimens","volume":"284","author":"Voelker","year":"2000","journal-title":"JID"},{"key":"10.1016\/j.jgar.2022.07.019_bib0031","unstructured":"World Health Organization. HIV drug resistance report 2012. http:\/\/www.who.int\/hiv\/pub\/drugresistance\/report2012\/en\/. [accessed 30 January 2020]"},{"key":"10.1016\/j.jgar.2022.07.019_bib0032","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","article-title":"HIV drug resistance","volume":"350","author":"Clavel","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.07.019_bib0033","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1093\/infdis\/jix137","article-title":"Global HIV antiretroviral drug resistance","volume":"216","author":"Godfrey","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.019_bib0034","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3329\/jhpn.v29i4.8444","article-title":"Prevalence of antiretroviral drug resistance mutations and HIV-1 subtypes among newly-diagnosed drug-na\u00efve persons visiting a voluntary testing and counselling centre in northeastern South Africa","volume":"29","author":"Nwobegahay","year":"2011","journal-title":"J Health Popul Nutr"},{"key":"10.1016\/j.jgar.2022.07.019_bib0035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1089\/aid.2006.22.202","article-title":"HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC)","volume":"22","author":"Vidal","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jgar.2022.07.019_sbref0036","series-title":"Global action plan on HIV drug resistance 2017\u20132021: 2018 progress report - HIV Drug Resistance","first-page":"14","volume":"11","author":"The World Health Organization","year":"2018"},{"key":"10.1016\/j.jgar.2022.07.019_bib0037","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1746-1596-7-138","article-title":"HIV-1 drug resistance genotyping from antiretroviral therapy (ART) na\u00efve and first-line treatment failures in Djiboutian patients","volume":"7","author":"Elmi Abar","year":"2012","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.jgar.2022.07.019_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jgar.2022.07.019_bib0039","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0032-1316472","article-title":"Liver toxicity of antiretroviral drugs","volume":"32","author":"Jones","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jgar.2022.07.019_bib0040","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-13-398","article-title":"Mother-to-child transmission of HIV and its predictors among HIV-exposed infants at a PMTCT clinic in northwest Ethiopia","volume":"13","author":"Koye","year":"2013","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.jgar.2022.07.019_bib0041","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1586\/14787210.2015.999667","article-title":"Prevention of mother-to-child transmission of HIV Type 1: The role of neonatal and infant prophylaxis","volume":"13","author":"Hurst","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2022.07.019_bib0042","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1097\/01.qai.0000248349.25630.3d","article-title":"Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study","volume":"43","author":"Nachega","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.07.019_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.16.1.18588","article-title":"Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review","volume":"16","author":"Gourlay","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jgar.2022.07.019_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-05854-w","article-title":"HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China","volume":"21","author":"Pang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.019_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofab106","article-title":"Drug resistance in HIV-positive adults during the initial year of antiretroviral treatment at Ethiopian health centers","volume":"8","author":"Reepalu","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.019_bib0046","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/hiv.13176","article-title":"Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia","volume":"23","author":"Tufa","year":"2022","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2022.07.019_bib0047","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/S2352-3018(20)30172-7","article-title":"Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study","volume":"7","author":"Gupta-Wright","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2022.07.019_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0035649","article-title":"Phylogeographic analysis of HIV-1 subtype C dissemination in southern Brazil","volume":"7","author":"Bello","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.019_bib0049","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/135965350801302S01","article-title":"Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia","volume":"13","author":"Abegaz","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2022.07.019_bib0050","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/AAC.00038-16","article-title":"Low-frequency drug resistance in HIV-infected Ugandans on antiretroviral treatment is associated with regimen failure","volume":"60","author":"Kyeyune","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2018","key":"10.1016\/j.jgar.2022.07.019_bib0051","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eclinm.2018.06.005","article-title":"Nationwide estimates of viral load suppression and acquired HIV drug resistance in Cameroon","volume":"1","author":"Tchouwa","year":"2018","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jgar.2022.07.019_bib0052","first-page":"1","article-title":"Drug resistance and virological failure among HIV-infected patients after a decade of antiretroviral treatment expansion in eight provinces of China","volume":"11","author":"Liang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.019_bib0053","article-title":"Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province","volume":"8","author":"Li","year":"2013","journal-title":"China. PLoS One"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:02:00Z","timestamp":1761991320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522001862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":53,"alternative-id":["S2213716522001862"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.07.019","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of HIV-1 drug resistance among patients failing first-line antiretroviral therapy in Ethiopia","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}